AI for Bio · Model

Germinal

Open-source de novo antibody and nanobody design pipeline that redesigns only the CDRs

AntibodiesAcademic labUnited StatesActiveSite entity page (Chinese site)中文

Overview

NameGerminal · aliases: Germinal
Full nameThe paper uses a single word as the name with no expanded form
Ambiguous names (not auto-linked)None
FamilyNot a family entry. A single pipeline with no family of versions
OrganizationStanford University (chemical engineering), Arc Institute
Organization typeAcademic lab
CountryUnited States
Model classDesign (antibody and nanobody CDR redesign)
DomainAntibodies (also: Proteins)
First release · paper revision
Basis: Preprint v1 posted (version API)
Note: The site recorded 2025-09-19, which is the date inside the DOI string source
Other milestones
  • First public evidence: · Preprint v1 posted source
  • Preprint v1: · Preprint v1 posted source
  • Code release: † · Latest repository commit (no tagged release) source
  • Official announcement: · News post from one of the participating institutes source
Latest update† partly verified · code release
Basis: Repository commits with no tagged release
Repository commits add scFv fixes, dependencies on an antibody language model and a scoring tool, and co-folding restraint fixes; there is no tagged release and no journal version was found.
Note: The commits mix fixes and dependencies, so whether this is a substantive update is arguable source
The most recent sourced event, not a claim that nothing changed since.
StatusActive · Repository commits within 12 months but no tagged release
OpennessCode: Open
Weights: Unclear
Code is open; it trains no weights of its own and depends on an antibody language model and a structure-modelling package whose licences are described second-hand
Benchmarks reported0 counted · none of the 44
Wet-lab validation2 recorded campaigns
Unverified fields† wetlab_validation, release_milestones.code_release, latest_update, open_status.code_license, open_status.weights, background.funding
As of2026-11-16

What it does

Redesigns the complementarity-determining regions on a fixed framework, scores binding with a co-folding model and constrains antibody-likeness with an antibody language model, aiming at epitope-directed antibodies without animal immunisation. It follows the same backpropagation-through-a-structure-model route as BindCraft, differing in its antibody focus and the added language model, and serves as the open academic counterpart to closed commercial models such as JAM-2 and Latent-X2.

Benchmarks reported

None of the 44 benchmarks. This model is on the zero-pairing list.

How it evaluates itself: Four-target nanobody campaign; Epitope check; Internal ablations

Other evaluations (outside the 44)

  • Four-target nanobody campaign (Wet-lab validation) Self-reported: Dozens of designs on each of four targets, reporter screen then binding measurement; values unverifiable this round
  • Epitope check (Wet-lab validation) Self-reported: Alanine substitutions at predicted interface residues to observe the change in binding
  • Internal ablations (Own task set) Self-reported: Compares co-folding guidance alone with added custom losses, and the antibody-language-model weight on developability and humanness measures

Developers report: an open pipeline that, without animal immunisation, yields nanomolar binders on all four tested targets from under about a hundred designs each, with humanness improved by antibody-language-model guidance.

Independent evidence: No independent evidence found. No third-party evaluation or independent reproduction was found, and it has no pairing among the 44 benchmarks here

Training data

Group in Figure 7: Public data + wet lab for validation only.

ClassValueDetail
a. Public databasesYesNo dedicated training; it reuses off-the-shelf weights from a co-folding model and two antibody language models, built on public sequence and structure archives source
b. Private or licensed dataNo
c. Own wet-lab data used for trainingNo
d. Wet lab used only for validationYesWet lab is for validation only, with testing described second-hand as involving a gene-synthesis company source

Wet-lab validation

Every rate carries its numerator and denominator. Claims that could not be verified are shown as unverified, without numbers; different paper versions are separate entries.

Four-target nanobody campaign (bioRxiv v1/v2)
Targets †unverified · Designs tested — · Hits — · Success — · Best affinity —

Denominator basis: Four targets with dozens of designs each, first screened by a reporter assay then measured for binding; the exact numerator and denominator could not be verified this round
The site previously published per-target hit counts, a 4-22% success range and nanomolar affinities; the full text was inaccessible this round
Executor: The preprint places the experiments in academic labs, with a gene-synthesis company involved in testing per second-hand sources

Self-reported · · †unverified · source
Epitope check (bioRxiv)
Targets †unverified · Designs tested — · Hits — · Success — · Best affinity —

Denominator basis: Alanine substitutions at predicted interface residues to see whether binding drops; no design count is given
The experiment speaks to where the designs bind, not to a success rate
Executor: The same academic labs as the main campaign

Self-reported · · †unverified · source

Background

  • Organization: A collaboration between a chemical engineering lab at a US university and a non-profit research institute in California, with no company entity; the institute's news post describes it as student-led.
  • Funding: Funding is listed in the preprint acknowledgements with no amounts given.
  • Products and partnerships: The output is the open pipeline itself; the same institute also produces genome and single-cell models such as Evo 2 and State.
  • Related models: BindCraft, JAM / JAM-2, Latent-X / Latent-X2, Evo 2

Reading notes

  1. Four targets with dozens of designs each is a small sample, and the work is an unreviewed preprint.
  2. The hit counts and success range previously published here could not be verified this round; the full text must be re-obtained before citing.
  3. The target list includes known easier cases, and generalisation to hard targets is unevidenced.
  4. Its value is as an open, inspectable counterpart to closed commercial antibody design models rather than scale.

Caveats

  1. All wet-lab figures were unverifiable this round, so the page gives no numbers.
  2. The first-release date is corrected away from the date inside the DOI string.
  3. The repository has no tagged release, so the latest update is a commit date.
  4. The pipeline trains no weights of its own and is bounded by its upstream models.
  5. It has no pairing among the 44 benchmarks covered here.

Sources

  1. Preprint 2025 (preprint)
  2. Preprint version API record (archive)
  3. Institute news post (official site)
  4. Code repository (repository)

Corrections

2 corrections
FieldWasNowBasisFound
first_release2025-09-19 (date in the DOI string)2025-09-24 (preprint v1 posted, version API)source2026-11-16
wetlab_validationPer-target hit counts, 4–22% success rates and 140–560 nM affinitiesThe full text was rate-limited this round; all marked unverified and the numbers withdrawnsource2026-11-16

Part of the AI for Bio benchmarks survey · all 112 models · open in the explorer. Record as of 2026-11-16.